Zepbound

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Lilly says 2026 looks good, as sales rocket in Q4

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.

News

Lilly points to long-lasting weight loss with orforglipron

Lilly breaks new ground for oral GLP-1 agonists with data showing it can help patients keep weight off after treatment with injectable therapies.

News

Queer Eye's Tan France to front Lilly obesity campaign

Eli Lilly has enlisted the aid of Tan France of US makeover show Queer Eye to change the narrative about obesity in a new campaign.

News

Company representatives with President Trump in the Oval Office

Novo, Lilly sign MFN pricing deal with Trump administration

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

Novo Nordisk to cut GLP-1 prices in tough US market

Head-to-head trial dents Novo Nordisk's obesity hopes

Lilly says 2026 looks good, as sales rocket in Q4

Lilly points to long-lasting weight loss with orforglipron

Queer Eye's Tan France to front Lilly obesity campaign

Novo, Lilly sign MFN pricing deal with Trump administration

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Zepbound

Editor's Picks